[FG] Kappos Ludwig

Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology Neuroimmunology & Neuroinflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.

Pontillo, G. et al. (2025) ‘More Than the Sum of Its Parts: Disrupted Core Periphery of Multiplex Brain Networks in Multiple Sclerosis’, Human Brain Mapping, 46(1). Available at: https://doi.org/10.1002/hbm.70107.

Lorscheider, Johannes et al. (2024) ‘Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network’, Journal of Neurology, Neurosurgery & Psychiatry, pp. jnnp–2024–334700. Available at: https://doi.org/10.1136/jnnp-2024-334700.

Woelfle, Tim et al. (2024) ‘Benchmarking Human–AI collaboration for common evidence appraisal tools’, Journal of Clinical Epidemiology. 12.09.2024, 175. Available at: https://doi.org/10.1016/j.jclinepi.2024.111533.

Geraldes, R. et al. (2024) ‘The influence of MOGAD on diagnosis of multiple sclerosis using MRI’, Nature Reviews Neurology, 20(10), pp. 620–635. Available at: https://doi.org/10.1038/s41582-024-01005-2.

Sastre-Garriga, J. et al. (2024) ‘Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives’, Neurology, 103(3). Available at: https://doi.org/10.1212/WNL.0000000000209677.

Diem, L et al. (2024) ‘Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers’, Multiple Sclerosis and Related Disorders, 86. Available at: https://doi.org/10.1016/j.msard.2024.105570.

Wendebourg, Maria Janina et al. (2024) ‘Cervical and thoracic spinal cord gray matter atrophy is associated with disability in patients with amyotrophic lateral sclerosis’, European Journal of Neurology, 31(6). Available at: https://doi.org/10.1111/ene.16268.

Lazzarotto, A. et al. (2024) ‘Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis’, Brain, 147(4), pp. 1331–1343. Available at: https://doi.org/10.1093/brain/awae024.

Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv [Preprint]. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.03.22.24304720.

Cagol, Alessandro et al. (2024) ‘Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis’, JAMA Neurology, 81(2), p. 143. Available at: https://doi.org/10.1001/jamaneurol.2023.4737.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.

Barakovic, Muhamed et al. (2024) ‘A novel imaging marker of cortical “cellularity” in multiple sclerosis patients’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-024-60497-6.

Benkert, Pascal et al. (2024) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology [Preprint]. Available at: https://doi.org/10.1002/ana.27096.

Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102. Available at: https://doi.org/10.1212/wnl.0000000000207768.

Cagol, Alessandro et al. (2024) ‘Advanced Quantitative MRI Unveils Microstructural Thalamic Changes Reflecting Disease Progression in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(6). Available at: https://doi.org/10.1212/NXI.0000000000200299.

Callegari, Ilaria et al. (2024) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’, Brain, 147, pp. 839–848. Available at: https://doi.org/10.1093/brain/awad424.

Cortese, Rosa et al. (2024) ‘Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis’, Annals of Neurology, 96, pp. 276–288. Available at: https://doi.org/10.1002/ana.26951.

Derfuss, T. et al. (2024) ‘Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials’, Therapeutic Advances in Neurological Disorders, 17. Available at: https://doi.org/10.1177/17562864241277736.

Filioglo, Andrei et al. (2024) ‘Corrigendum: Tandem occlusions involving the internal carotid and anterior cerebral arteries—A rare form of stroke: results from the multicenter EVATRISP collaboration study (Frontiers in Neurology, (2022), 13, (1024891), 10.3389/fneur.2022.1024891)’, Frontiers in Neurology, 15. Available at: https://doi.org/10.3389/fneur.2024.1450372.

Gomes, Ana Beatriz Ayroza Galvão Ribeiro et al. (2024) ‘Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease’, Neurology: Neuroimmunology and NeuroInflammation, 12(1). Available at: https://doi.org/10.1212/NXI.0000000000200347.

Kappos, Ludwig et al. (2024) ‘Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension’, Journal of Neurology, 271, pp. 642–657. Available at: https://doi.org/10.1007/s00415-023-11943-4.

Kaufmann, Josefin E. et al. (2024) ‘Toward Individual Treatment in Cervical Artery Dissection: Subgroup Analysis of the TREAT-CAD Randomized Trial’, Annals of Neurology [Preprint]. Available at: https://doi.org/10.1002/ana.26886.

Kaufmann, Josefin E. et al. (2024) ‘Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis’, JAMA Neurology, 81, pp. 630–637. Available at: https://doi.org/10.1001/jamaneurol.2024.1141.

Khalil, Michael et al. (2024) ‘Neurofilaments as biomarkers in neurological disorders — towards clinical application’, Nature Reviews Neurology, 20, pp. 269–287. Available at: https://doi.org/10.1038/s41582-024-00955-x.

Mallucci, Giulia et al. (2024) ‘Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis’, Multiple Sclerosis Journal [Preprint]. Available at: https://doi.org/10.1177/13524585241305966.

Oechtering, Johanna et al. (2024) ‘Complement Activation Is Associated With Disease Severity in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(2). Available at: https://doi.org/10.1212/NXI.0000000000200212.

Papadopoulou, A. et al. (2024) ‘Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus’, Clinical Neurophysiology, 161, pp. 122–132. Available at: https://doi.org/10.1016/j.clinph.2024.02.020.

Pontillo, Giuseppe et al. (2024) ‘Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap’, Neurology, 103. Available at: https://doi.org/10.1212/WNL.0000000000209976.

Sanabria-Diaz, Gretel et al. (2024) ‘Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis’, Annals of Neurology [Preprint]. Available at: https://doi.org/10.1002/ana.27102.

Steinegger, L. et al. (2024) ‘Acute leukoencephalopathy associated with daratumumab treatment in POEMS syndrome: a case report’, Frontiers in Immunology, 15. Available at: https://doi.org/10.3389/fimmu.2024.1451693.

Wali, Nabila et al. (2024) ‘Endovascular treatment in patients with acute ischemic stroke presenting beyond 6 h after symptom onset: An international multicenter cohort study of the EVA-TRISP collaboration’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241277437.

Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), p. 1317. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.

Baumgartner P et al. (2023) ‘Safety and effectiveness of IV Thrombolysis in retinal artery occlusion: A multicenter retrospective cohort study’, European Stroke Journal, 8(4), pp. 966–973. Available at: https://doi.org/10.1177/23969873231185895.

Diouf I et al. (2023) ‘Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: Causal inference to emulate a multiarm randomised trial’, Journal of Neurology, Neurosurgery and Psychiatry, 94(12), pp. 1004–1011. Available at: https://doi.org/10.1136/jnnp-2023-331499.

Hauser, S.L. et al. (2023) ‘Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis’. Elsevier B.V. Available at: https://doi.org/10.1016/j.msard.2023.105308.

Montalban, X. et al. (2023) ‘Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)’. Elsevier B.V., 80. Available at: https://doi.org/10.1016/j.msard.2023.105328.

Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis’, JAMA Neurology, 80(11), p. 1232. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.

Callegari, I. et al. (2023) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.09.29.560121.

Hauser S.L. et al. (2023) ‘The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment’, Neurology and Therapy, 12(5), pp. 1491–1515. Available at: https://doi.org/10.1007/s40120-023-00518-0.

Seystahl K et al. (2023) ‘IV Thrombolysis With or Without Endovascular Treatment for Suspected Ischemic Stroke in Patients With Intracranial Tumors’, Neurology, 101(12), pp. E1241–E1255. Available at: https://doi.org/10.1212/WNL.0000000000207624.

Harding-Forrester, Sam et al. (2023) ‘Disability accrual in primary and secondary progressive multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94(9), pp. 707–717. Available at: https://doi.org/10.1136/jnnp-2022-330726.

Bar-Or, Amit et al. (2023) ‘Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials’, eBioMedicine, 93. Available at: https://doi.org/10.1016/j.ebiom.2023.104662.

Pless S et al. (2023) ‘Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study’, Journal of Neurology, 270(7), pp. 3451–3463. Available at: https://doi.org/10.1007/s00415-023-11671-9.

Cortese R. et al. (2023) ‘Clinical and MRI measures to identify non-acute MOG-antibody disease in adults’, Brain, 146(6), pp. 2489–2501. Available at: https://doi.org/10.1093/brain/awac480.

Pfeuffer S. et al. (2023) ‘Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab’, Neurology(R) neuroimmunology & neuroinflammation, 10(3). Available at: https://doi.org/10.1212/nxi.0000000000200104.

Traenka, Christopher et al. (2023) ‘Recanalization Therapies for Large Vessel Occlusion Due to Cervical Artery Dissection: A Cohort Study of the EVA-TRISP Collaboration’, Journal of Stroke, 25(2), pp. 272–281. Available at: https://doi.org/10.5853/jos.2022.03370.

Tsagkas, Charidimos et al. (2023) ‘Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis’, Multiple Sclerosis Journal, 29(6), pp. 702–718. Available at: https://doi.org/10.1177/13524585221139152.

Agosti, Reto et al. (2023) ‘Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study’, Pain and Therapy, 12(2), pp. 575–591. Available at: https://doi.org/10.1007/s40122-023-00484-3.

Cagol A. et al. (2023) ‘Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis’, Journal of Neurology, 270(4), pp. 2139–2148. Available at: https://doi.org/10.1007/s00415-022-11535-8.

Diouf I. et al. (2023) ‘Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis’, European Journal of Neurology, 30(4), pp. 1014–1024. Available at: https://doi.org/10.1111/ene.15706.

Vrenken H. et al. (2023) ‘Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a’, Journal of Neurology, 270(4), pp. 2271–2282. Available at: https://doi.org/10.1007/s00415-022-11554-5.

Hauser S.L. et al. (2023) ‘Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 10(2). Available at: https://doi.org/10.1212/nxi.0000000000200094.

Meinel, Thomas R. et al. (2023) ‘Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants’, JAMA Neurology, 80(3), pp. 233–243. Available at: https://doi.org/10.1001/jamaneurol.2022.4782.

Al-Ajlan FS et al. (2023) ‘Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial’, Stroke, 54(3), pp. 715–721. Available at: https://doi.org/10.1161/STROKEAHA.121.038475.

Bakker, M.K. et al. (2023) ‘Genetic Risk Score for Intracranial Aneurysms: Prediction of Subarachnoid Hemorrhage and Role in Clinical Heterogeneity’, Stroke, 54(3), pp. 810–818. Available at: https://doi.org/10.1161/strokeaha.122.040715.

Kuhle J et al. (2023) ‘Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial’, Multiple Sclerosis Journal, 29(3), pp. 385–394. Available at: https://doi.org/10.1177/13524585221144742.

Tsagkas C et al. (2023) ‘Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis’, Multiple Sclerosis and Related Disorders, 71, p. 104545. Available at: https://doi.org/10.1016/j.msard.2023.104545.

Marto JP et al. (2023) ‘Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19’, Neurology, 100(7), pp. E739–E750. Available at: https://doi.org/10.1212/WNL.0000000000201537.

Wenger A.L. et al. (2023) ‘An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis’, Frontiers in Neuroscience, 17. Available at: https://doi.org/10.3389/fnins.2023.1007580.

Tsagkas C et al. (2023) ‘Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis’, American Journal of Neuroradiology, 44(2), pp. 218–227. Available at: https://doi.org/10.3174/ajnr.A7756.

Ziemssen T. et al. (2023) ‘Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies’, Neurology: Neuroimmunology and NeuroInflammation, 10(1). Available at: https://doi.org/10.1212/nxi.0000000000200064.

Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80, pp. 1317–1325. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.

Achtnichts, Lutz et al. (2023) ‘Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: Primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)’, BMJ Neurology Open, 5. Available at: https://doi.org/10.1136/bmjno-2022-000304.

Alexander Salerno et al. (2023) ‘BEST REVASCULARIZATION APPROACH FOR POSTERIOR CIRCULATION STROKES WITH ISOLATED VERTEBRAL ARTERY OCCLUSIONS: RESULTS FROM THE “BRAVO” RETROSPECTIVE STUDY ’, in European Stroke Organisation Conference . Munich, Germany (European Stroke Organisation Conference ).

Alexandros Polymeris et al. (2023) ‘OUTCOMES OF ATRIAL FIBRILLATION KNOWN BEFORE OR DETECTED AFTER ISCHEMIC STROKE: ROLE OF ANTICOAGULATION’, in European Stroke Organisation Conference. Munich, Germany (European Stroke Organisation Conference).

Altersberger, Valerian L. et al. (2023) ‘Intravenous Thrombolysis 4.5–9 Hours After Stroke Onset: A Cohort Study from the TRISP Collaboration’, Annals of Neurology. 28.04.2023, 94(2), pp. 309–320. Available at: https://doi.org/10.1002/ana.26669.

Bühler A et al. (2023) ‘Recurrent disability progression endpoints in multiple sclerosis clinical trials’, Multiple Sclerosis Journal, 29(1), pp. 130–139. Available at: https://doi.org/10.1177/13524585221125382.

Callegari, Ilaria et al. (2023) ‘Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150040.

Cerdá-Fuertes, Nuria et al. (2023) ‘Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis’, Therapeutic Advances in Neurological Disorders, 16. Available at: https://doi.org/10.1177/17562864221150312.

Chen, Xinjie et al. (2023) ‘Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients’, NeuroImage: Clinical, 37. Available at: https://doi.org/10.1016/j.nicl.2023.103349.

Dittrich, Tolga D et al. (2023) ‘Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: Prevalence, treatment, and clinical implications – the PLEURA study’, European Stroke Journal, 8, pp. 549–556. Available at: https://doi.org/10.1177/23969873231151488.

Dittrich, Tolga D et al. (2023) ‘Mechanical thrombectomy for large vessel occlusion between 6 and 24 h: outcome comparison of DEFUSE-3/DAWN eligible versus non-eligible patients’, International Journal of Stroke, 18, pp. 697–703. Available at: https://doi.org/10.1177/17474930221140793.

Dittrich, Tolga D. et al. (2023) ‘Mechanical Thrombectomy Versus Best Medical Treatment in the Late Time Window in Non-DEFUSE-Non-DAWN Patients: A Multicenter Cohort Study’, Stroke, 54, pp. 722–730. Available at: https://doi.org/10.1161/strokeaha.122.039793.

Gentile G. et al. (2023) ‘The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study’, NeuroImage: Clinical, 38. Available at: https://doi.org/10.1016/j.nicl.2023.103397.

Granziera, Cristina, Derfuss, Tobias and Kappos, Ludwig (2023) ‘Time to Change the Current Clinical Classification of Multiple Sclerosis?’, JAMA Neurology, 80, pp. 128–130. Available at: https://doi.org/10.1001/jamaneurol.2022.4156.

JE Kaufmann et al. (2023) ‘Towards Individual Treatment in Cervical Artery Dissection—An In‑Depth Analysis of the TREAT‑CAD Randomised Trial’, in Annual Meeting of the Swiss Neurological Society and Swiss Society of Neurosurgery. Zurich (Annual Meeting of the Swiss Neurological Society and Swiss Society of Neurosurgery).

Josefin E. Kaufmann et al. (2023) ‘TOWARDS INDIVIDUAL TREATMENT IN CERVICAL ARTERY DISSECTION - AN INDEPTH ANALYSIS OF THE TREAT-CAD RANDOMISED TRIAL’, in European Stroke Organisation Conference. Munich, Germany (European Stroke Organisation Conference).

Kappos L., Barkhof F. and Uitdehaag B. (2023) ‘Otto van Eikema Hommes – 7 February 1932 – 16 August 2022’, Multiple Sclerosis Journal, 29(1), pp. 6–7. Available at: https://doi.org/10.1177/13524585221139153.

K. Seystahl et al. (2023) ‘ INTRAVENOUS THROMBOLYSIS WITH OR WITHOUT ENDOVASCULAR TREATMENT FOR SUSPECTED ISCHEMIC STROKE IN PATIENTS WITH INTRACRANIAL TUMORS’, in 18th Meeting of the European Association of Neuro-Oncology. Rotterdam, Netherlands (18th Meeting of the European Association of Neuro-Oncology).

Lyrer, Flurina et al. (2023) ‘Atrial Fibrillation Detected before or after Stroke: Role of Anticoagulation’, Annals of Neurology, 94, pp. 43–54. Available at: https://doi.org/10.1002/ana.26654.

Todea, Alexandra Ramona et al. (2023) ‘A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients’, Journal of Magnetic Resonance Imaging, 58, pp. 864–876. Available at: https://doi.org/10.1002/jmri.28618.

Tolga Dittrich et al. (2023) ‘APICAL PULMONARY LESIONS SUSPECTED OF MALIGNANCY VISIBLE ON NECK CT ANGIOGRAPHY PERFORMED FOR ACUTE STROKE: PREVALENCE, REATMENT AND CLINICAL IMPLICATIONS – THE PLEURA STUDY’, in European Stroke Organisation Conference. Munich, Germany (European Stroke Organisation Conference).

Woelfle T et al. (2023) ‘Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective’, Journal of Medical Internet Research, 25, p. e44428. Available at: https://doi.org/10.2196/44428.

Woelfle, Tim et al. (2023) ‘Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity’, Multiple Sclerosis and Related Disorders, 80. Available at: https://doi.org/10.1016/j.msard.2023.105104.

Woelfle T et al. (2023) ‘Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study’, Journal of Neurology, 270(1), pp. 262–271. Available at: https://doi.org/10.1007/s00415-022-11306-5.

Filioglo A et al. (2022) ‘Tandem occlusions involving the internal carotid and anterior cerebral arteries—A rare form of stroke: Results from the multicenter EVATRISP collaboration study’, Frontiers in Neurology , 13, p. 1024891. Available at: https://doi.org/10.3389/fneur.2022.1024891.

Chang I et al. (2022) ‘Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis’, Multiple Sclerosis Journal, 28(14), pp. 2263–2273. Available at: https://doi.org/10.1177/13524585221114997.

Meaton I et al. (2022) ‘Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis’, Multiple Sclerosis Journal, 28(14), pp. 2212–2220. Available at: https://doi.org/10.1177/13524585221118677.

Ovchinnikov, Arkady and Findling, Oliver (2022) ‘An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis’, Wiener Medizinische Wochenschrift, 172(15-16), pp. 359–364. Available at: https://doi.org/10.1007/s10354-022-00939-w.

Sztajzel RF et al. (2022) ‘Carotid plaque surface echogenicity predicts cerebrovascular events: An Echographic Multicentric Swiss Study’, Journal of Neuroimaging, 32(6), pp. 1142–1152. Available at: https://doi.org/10.1111/jon.13026.

Roos I et al. (2022) ‘Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis’, Neurology, 99(17), pp. E1926–E1944. Available at: https://doi.org/10.1212/WNL.0000000000201029.

Leppert D et al. (2022) ‘Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials’, Neurology, 99(14), p. 631. Available at: https://doi.org/10.1212/WNL.0000000000201277.

Altersberger VL et al. (2022) ‘Thrombolysis in stroke patients with elevated inflammatory markers’, Journal of Neurology, 269(10), pp. 5405–5419. Available at: https://doi.org/10.1007/s00415-022-11173-0.

Cree BA et al. (2022) ‘Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial’, Multiple Sclerosis Journal, 28(12), pp. 1944–1962. Available at: https://doi.org/10.1177/13524585221102584.

Kalincik T et al. (2022) ‘Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS’, Multiple Sclerosis Journal, 28(11), pp. 1752–1761. Available at: https://doi.org/10.1177/13524585221084577.

Sprenger T et al. (2022) ‘Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies’, Multiple Sclerosis Journal, 28(11), pp. 1719–1728. Available at: https://doi.org/10.1177/13524585221089534.

Signori A et al. (2022) ‘Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network’, Journal of Neurology, Neurosurgery and Psychiatry, 94(1), pp. 23–30. Available at: https://doi.org/10.1136/jnnp-2022-329987.

Arnold DL et al. (2022) ‘Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial’, Multiple Sclerosis Journal, 28(10), pp. 1526–1540. Available at: https://doi.org/10.1177/13524585221076717.